

Capstone Therapeutics

Pharma & biotech

15 July 2014

A new class of cardiovascular drug

First clinical data for AEM-28, an Apo-E mimetic, is expected during H214, which could pave the way for continued development in an orphan cardiovascular (CV) indication, although additional funds will likely be needed if data are positive. Preclinical data suggest AEM-28 can lower cholesterol and protect the artery wall; this profile could have utility in broader CV indications, although development is still at an early stage.

A cholesterol buster with protective effects

AEM-28 is a mimetic of Apolipoprotein E (Apo-E), a protein involved in lipid and cholesterol metabolism, which clears postprandial (after eating) lipoproteins. AEM-28 could enhance and increase the ability of the liver to clear these lipoproteins, reducing cholesterol and therefore potentially cardiovascular (CV) risk. In addition it could have a protective effect on the artery wall.

A stone's throw from key AEM-28 catalysts

AEM-28 has completed a Phase Ia study with full data expected in Q314. Safety was observed in the first five escalating doses with the sixth dose still under evaluation. According to the protocol, these safety findings allowed progression to the [Phase Ib/IIa](#) multiple ascending dose trial in patients with refractory hypercholesterolemia; data are expected in Q414. AEM-28 is initially being developed for homozygous familial hypercholesterolemia (HoFH), an inherited genetic orphan indication, where both Juxtapid (US approval December 2012; EU approval July 2013; 2013 US sales \$48.5m) and Kynamro (US approval January 2013; EU negative opinion; sales undisclosed) were approved based on small, single Phase III trials using a cholesterol reduction endpoint. Capstone believes HoFH could be a \$200m market.

Broader potential in significant indications

In preclinical models, AEM-28 has shown more rapid cholesterol clearance than typical cholesterol-lowering drug classes in addition to a reduction in atherosclerosis. This unique profile could have a role in larger indications, potentially including acute coronary syndrome (ACS), peripheral artery disease (PAD) and diabetes.

Valuation: Undemanding EV for CV

Capstone had \$5.5m net cash at end-March, suggesting an EV of c \$7m, relatively undemanding for a company with a cardiovascular (CV) focus. \$1.7m cash is allocated to LipimetiX Development, a joint venture for AEM-28 in which Capstone has 60% ownership. Positive AEM-28 clinical data expected during H214 could trigger a re-rating. However, further funds will be needed for future development.

Historic financials

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (\$)	Yield (%)
12/11	0.0	(9.9)	(0.24)	0.0	N/A	N/A
12/12	0.0	(4.1)	(0.09)	0.0	N/A	N/A
12/13	0.0	(4.1)	(0.10)	0.0	N/A	N/A

Source: Capstone Therapeutics

Price \$0.3
Market cap \$12m

Share price graph



Share details

Code CAPS
Listing OTCQB
Shares in issue 40.89m

Business description

Capstone Therapeutics' lead candidate AEM-28 is currently in a Phase I/II clinical trial for orphan disease homozygous familial hypercholesterolemia. AEM-28 also has potential in broader CV indications. Capstone owns 60% of AEM-28 through a JV with LipimetiX Development.

Bull

- Initial target indication could allow for shorter and smaller trials than typical CV development.
- Broader CV disorders and lipid lowering could be significant future markets.
- Upcoming clinical catalysts in H214.

Bear

- Only preclinical data available to date.
- Limited cash to pursue further trials.
- Lawsuit uncertainty relating to bone growth stimulation business, exited in 2003.

Analysts

Dr Philippa Gardner +44 (0)20 3681 2521
Christian Glennie +44 (0)20 3077 5727

healthcare@edisongroup.com

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Capstone Therapeutics and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2014]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.